Knights of Columbus Asset Advisors LLC Sells 54,077 Shares of Adaptive Biotechnologies Corporation $ADPT

Knights of Columbus Asset Advisors LLC decreased its position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 28.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 137,330 shares of the company’s stock after selling 54,077 shares during the quarter. Knights of Columbus Asset Advisors LLC owned approximately 0.09% of Adaptive Biotechnologies worth $2,230,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC grew its stake in shares of Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after purchasing an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Adaptive Biotechnologies by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the last quarter. Caxton Associates LLP bought a new position in Adaptive Biotechnologies during the 1st quarter valued at approximately $93,000. New York State Common Retirement Fund lifted its holdings in Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after buying an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock worth $4,417,000 after buying an additional 333,379 shares during the last quarter. 99.17% of the stock is owned by institutional investors.

Analyst Ratings Changes

ADPT has been the subject of a number of recent analyst reports. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a report on Friday, February 6th. JPMorgan Chase & Co. cut their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Guggenheim reissued a “buy” rating and set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Finally, Morgan Stanley cut their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT opened at $15.19 on Friday. Adaptive Biotechnologies Corporation has a 1-year low of $9.05 and a 1-year high of $20.76. The firm’s 50-day moving average price is $13.88 and its 200-day moving average price is $15.55. The company has a market capitalization of $2.43 billion, a PE ratio of -46.03 and a beta of 2.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.20) earnings per share. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Julie Rubinstein sold 19,037 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $14.23, for a total transaction of $270,896.51. Following the completion of the sale, the chief operating officer owned 377,802 shares in the company, valued at approximately $5,376,122.46. This represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kyle Piskel sold 3,115 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $13.04, for a total transaction of $40,619.60. Following the completion of the transaction, the chief financial officer directly owned 256,725 shares in the company, valued at approximately $3,347,694. The trade was a 1.20% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 2,237,392 shares of company stock valued at $31,269,192 over the last 90 days. Company insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.